Combination therapy for heart failure does not reduce risk of CV death or rehospitalization

March 11, 2013

Among patients hospitalized for heart failure (HF) with reduced left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction), initiation of the medication aliskiren in addition to standard therapy did not reduce cardiovascular death or HF rehospitalization at 6 or 12 months after discharge, according to a study published online by JAMA.

"Inhibition of the renin-angiotensin-aldosterone system [RAAS; the regulation of sodium balance, fluid volume, and blood pressure by secretion of renin in response to reduced of the kidney] has long been recognized as a life-prolonging therapy for patients with with reduced LVEF, and angiotensin-converting enzyme (ACE) inhibitors, angiotensin II (ARBs), and mineralocorticoid (MRAs) are recommended by all major national guidelines. However, although the benefits of these treatments are undisputed, these agents induce a compensatory increase in renin [an enzyme secreted by the kidneys] and downstream RAAS intermediaries that may partially offset RAAS blocking effects," according to background information in the article.

The direct renin inhibitors (DRIs) represent another pharmacologically distinct method for RAAS blockade. Aliskiren, an orally active DRI, has demonstrated a favorable hemodynamic and neurohormonal profile in patients with HF. "Despite current evidence-based therapies, patients with hospitalization for HF (HHF) face postdischarge mortality and rehospitalization rates as high as 15 percent and 30 percent, respectively, within 60 to 90 days. Incomplete suppression of the RAAS may contribute to the exceptionally high postdischarge event rate," the authors write.

Mihai Gheorghiade, M.D., of the Northwestern University Feinberg School of Medicine, Chicago, and colleagues conducted a study (the ASTRONAUT randomized trial) to examine whether the addition of a DRI (aliskiren) to standard therapy would improve long-term outcomes in HHF patients. The study included hemodynamically stable HHF patients a median (midpoint) 5 days after admission who met certain criteria. Patients were recruited from 316 sites across North and South America, Europe, and Asia between May 2009 and December 2011. The follow-up period ended in July 2012.

All patients received 150 mg (increased to 300 mg as tolerated) of aliskiren or placebo daily, in addition to standard therapy. The study drug was continued after discharge for a median 11.3 months.

The final group for efficacy analyses included 1,615 patients (808 assigned to aliskiren, 807 assigned to placebo). At randomization, patients were receiving diuretics (95.9 percent), beta-blockers (82.5 percent), or ARBs (84.2 percent), and MRAs (57.0 percent).There were no major differences between the 2 treatment groups at the time of randomization. The average age was 65 years.

"In total, 24.9 percent of patients receiving aliskiren (77 cardiovascular [CV] deaths, 153 HF hospitalizations) and 26.5 percent of patients receiving placebo (85 CV deaths, 166 HF rehospitalizations) experienced the primary end point [ or HF rehospitalization] at 6 months. At 12 months, the event rates were 35.0 percent for the aliskiren group (126 CV deaths, 212 HF rehospitalizations) and 37.3 percent for the placebo group (137 CV deaths, 224 HF rehospitalizations)," the authors write.

During the overall follow-up period (ranging from 0.1 to 31.2 months), the total hospitalization rates (i.e., percentage of patients hospitalized for any reason) in the aliskiren and placebo groups were 48.1 percent and 49.1 percent, respectively. The HF hospitalization rates within 12 months were 26.2 percent in the aliskiren group and 27.8 percent in the placebo group.

The researchers also found that the rates of hyperkalemia (higher than normal levels of potassium in the circulating blood), hypotension, and renal impairment/renal failure were higher in the aliskiren group compared with placebo.

"The results of the ASTRONAUT study do not support the routine administration of aliskiren, in addition to evidence-based therapy, to patients hospitalized for worsening chronic HF. Subgroup analysis is consistent with previous reports of poor outcomes with the use of aliskiren in patients with diabetes mellitus [DM] already taking RAAS inhibitors. Further investigations are needed to evaluate the effects of renin inhibition in a large cohort of HHF patients that excludes with DM," the authors conclude.

Explore further: Median follow-up results from the ALTITUDE study

More information: doi:10.1001/jama.2013.1954

The study is being released early to coincide with its presentation at the American College of Cardiology's annual Scientific Sessions.

Related Stories

Median follow-up results from the ALTITUDE study

August 27, 2012
Preliminary results from the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) do not support administration of aliskiren on top of standard therapy with renin-angiotensin-aldosterone system (RAAS) ...

Advancing understanding of treatment through clinical trials

November 4, 2012
Three late-breaking studies presented during the American Society of Nephrology's Annual Kidney Week provide new information on drugs being tested in patients with diabetes or kidney disease.

The effect of eplerenone vs. placebo on cardiovascular mortality

August 29, 2011
Today results from a new sub-analysis of the EMPHASIS-HF study showed significant reductions in death and hospitalization for five pre-defined high-risk patient sub-groups with chronic heart failure (CHF) and mild symptoms ...

Hospitalization for heart failure among Medicare patients has declined substantially

October 18, 2011
Between 1998 and 2008, heart-failure related hospitalizations declined substantially among Medicare patients, but at a lower rate for black men, according to a study in the October 19 issue of JAMA. Also, 1-year mortality ...

Recommended for you

New discovery could reverse tissue damage caused by heart attacks

July 25, 2017
A new discovery by University of Bristol scientists helps to explain how cells which surround blood vessels, called pericytes, stimulate new blood vessels to grow with the hormone 'leptin' playing a key role. Leptin is produced ...

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.